# PRD Quality Review — SecOpinion

## Overall verdict
This PRD is decision-ready and unusually honest about what it doesn't know — trade-offs, deferrals, and one significant accepted risk (POC-scoped compliance) are stated as such rather than smoothed over. The main things holding it back from "strong across the board" are one unresolved metric gap (doctor-verification integrity has no Success Metric) and a small mechanical Assumptions Index gap. Nothing found here should block moving to Architecture.

## Decision-readiness — strong
Real decisions are stated as decisions: the free→paid pivot, single-Admin verification, the 5-day auto-refund with zero platform cut, and the explicit choice to defer formal compliance work all read as decisions with stated reasoning, not hedged "considerations." The POC compliance risk flag (§4.6) is a good example of an objection being surfaced rather than dodged.

### Findings
- **low** Payout split left as a range (§4/FR-12, Open Q5) — acceptable at PRD stage since it's flagged, but Architecture cannot finalize the payment/ledger design until this resolves.

## Substance over theater — strong
Three personas (Ramesh, Priya, Dr. Iyer), each driving a distinct real decision (guardian/minor registration model, urgency+payment flow, SLA/payout mechanics) — no persona theater. Vision is specific to this product's actual thesis (profit-driven overtreatment), not swappable into another healthcare PRD. NFRs are mostly product-specific (currency-safe money storage, PCI offload via gateway) rather than generic boilerplate.

### Findings
- **low** FR-9's "visually distinguished and/or prioritized" is a soft mechanism description rather than a bound — fine for PRD-level, but Architecture will need to pick one.

## Strategic coherence — strong
Clear thesis: profit-driven overtreatment creates a gap SecOpinion exists to close. SM-1 (surgery-avoidance rate) directly validates that thesis rather than measuring vanity activity. Counter-metrics (SM-C1, SM-C2) protect against the two most obvious ways to game the primary metrics (loosening doctor verification, rushing opinions).

## Done-ness clarity — adequate
Most FRs carry testable consequences. A few load-bearing mechanics are explicitly still open (payout split %, payout timing) — correctly captured as Open Questions rather than silently assumed, which is the right call, but it does mean Architecture inherits 2-3 real unresolved mechanics.

### Findings
- **medium** FR-11/FR-13 interaction (late-opinion-after-refund) is flagged as open (Open Q8) but has real product consequences (does the doctor get anything? does the patient get contacted again?) — worth resolving before Architecture designs the Case state machine, not just before Epics.

## Scope honesty — strong
Non-Goals section does real work (5 explicit exclusions). Assumptions Index and Open Questions are both substantive, not rhetorical. `[NOTE FOR PM]` callouts sit at genuine tensions (refund cost with zero revenue, POC compliance risk) rather than safe checkpoints. Open-item density (8 Open Questions + 13 Assumptions) is moderate-high for a Launch-stakes PRD — acceptable here because none were assessed as phase-blockers, but worth the user's awareness that Architecture will need to close several of these, not zero.

## Downstream usability — strong
Glossary is present and FR/UJ/SM IDs are contiguous and cross-references resolve (verified during the FR renumbering pass). Each UJ has a named protagonist. Terms used consistently (Case, Opinion, Urgency Tier, Response SLA) across Vision, Features, and Glossary.

## Shape fit — strong
Multi-stakeholder consumer/professional product (patient + doctor) → named-protagonist UJs are load-bearing and present. Not over-formalized (no unnecessary enterprise sections like Stakeholders/Approvals) and not under-formalized (Compliance and Regulatory section exists even though scoped down, rather than omitted).

## Mechanical notes
- **Assumptions Index gap:** the inline `[ASSUMPTION: a minimal internal admin screen, not a polished product surface...]` in FR-5 is not indexed in §9. Low severity, easy fix.
- No glossary drift found (Case/Patient/Doctor/Opinion/Urgency Tier used consistently).
- No ID gaps or duplicates found in FR-1 through FR-14 or UJ-1 through UJ-3.
- No broken cross-references found (FR-9, FR-11, FR-12, FR-13 cross-refs all resolve correctly after the earlier renumbering pass).
